Ichnos launched with a running start in 2019 when it was spun-out as an innovation unit by generics leader Glenmark, and subsequently focused on developing novel multispecific antibody ...

In the past few years, multispecific antibodies, such as trispecific, bispecific, and tetraspecific, have become popular in antibody therapeutics. Compared to conventional monospecific antibodies ...

Our complete multispecific antibody development solutions, covering various phases of the development process, such as antibody development and optimization, druggability assessment, animal model ...

The funding is expected to support the development of a second novel multispecific antibody to SARS-CoV-2 from preclinical through Phase 1 trials, as well as preclinical work on gene-based ...

Alec Nielsen, co-founder and CEO, Asimov Ramanath Bhandari, RevOpsis co-founder and CEO, commented: "RevOpsis is committed to the rapid discovery and development of novel multispecific therapies ...

RevOpsis says it is committed to the rapid discovery and development of novel multispecific therapies utilizing its modular ...

Ramanath Bhandari, RevOpsis co-founder and CEO, commented: “RevOpsis is committed to the rapid discovery and development of novel multispecific therapies utilizing our modular RevMod™ Platform ...

(RTTNews) - AbbVie (ABBV) and EvolveImmune Therapeutics announced a collaboration and option-to-license agreement to develop multispecific biologics for multiple targets in oncology. The ...